Encompass Health CORP

Encompass Health Corporation announced the issuance of $500 million in aggregate principal amount of 5.875% Senior Notes due 2034 to fund debt repayment and operational expenses.

Encompass Health Corporation has priced a $500 million private offering of 5.875% senior notes due 2034 to refinance existing debt.

Encompass Health Corporation's annual meeting saw strong shareholder approval for director elections, auditor ratification, and executive compensation.

Encompass Health reported strong first-quarter 2026 growth and raised its full-year financial guidance.

Encompass Health reported robust fourth-quarter and full-year 2025 results, driven by capacity expansion and strong operational performance, alongside optimistic 2026 guidance.

Encompass Health Corporation announced the election of Cain A. Hayes, former CEO of Point32Health, to its Board of Directors, bringing significant healthcare payor expertise.

Encompass Health reported a 9% increase in net operating revenues for Q1 2026, driven by volume growth and pricing improvements.

Encompass Health delivered double‑digit year‑to‑date growth, expanded capacity, redeemed 2025 notes, and flagged a 2.9% Medicare rate lift effective October 1 while noting ongoing RCD audit risk.

Encompass Health Corporation announced significant revenue and earnings growth for Q2 2025, driven by increased patient volumes and favorable pricing, alongside strategic expansion and a dividend increase.

Encompass Health Corporation reports a 10.6% increase in net operating revenues for the first quarter of 2025, driven by volume growth and increased pricing.

Encompass Health Corporation reported a significant increase in net operating revenues for the third quarter of 2024, primarily driven by volume growth.

Encompass Health Corporation reported a 9.6% increase in net operating revenues for the second quarter of 2024, primarily driven by volume growth.

Encompass Health Corporation reports robust 2025 financial performance driven by volume growth and strategic hospital expansions, alongside ongoing regulatory challenges and a positive long-term outlook.

Encompass Health Corporation demonstrates robust growth in 2024, driven by increased patient volumes and strategic hospital expansions, while navigating regulatory challenges in the post-acute healthcare sector.

Encompass Health's 2023 annual report highlights a year of revenue growth, strategic expansion, and ongoing efforts to navigate the complex healthcare regulatory landscape.

Christopher R Reidy, a Director of Encompass Health Corp, reported multiple transactions in common stock on July 15, 2026.

Edward M Christie Iii, a Director of Encompass Health Corp, reported multiple transactions in common stock on July 15, 2026.

Terrance Williams, a Director of Encompass Health Corp, received 29 shares of common stock on July 15, 2026.

Nancy M Schlichting, a Director of Encompass Health Corp, received 40 shares of common stock on July 15, 2026.

Kevin J. O'Connor, a Director of Encompass Health Corp, received 19 shares of common stock on July 15, 2026.

Leslye G Katz, a Director of Encompass Health Corp, received 85 shares of common stock on July 15, 2026.

Encompass Health Corporation has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, and executive compensation.

Encompass Health's proxy statement details proposals for the 2025 annual meeting, including director elections, auditor ratification, executive compensation, and approval of a new omnibus performance incentive plan.

Encompass Health's proxy statement details proposals for the 2024 annual meeting, including director elections, auditor ratification, executive compensation, and a diversity, equity, and inclusion report request.

Vanguard Portfolio Management has reported a 4.97% stake in Encompass Health Corp., holding 4,935,748 shares as of June 30, 2026.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.26% beneficial ownership stake in Encompass Health Corp.

Vanguard Portfolio Management has reported beneficial ownership of 5% of Encompass Health Corp's common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G for Encompass Health Corp, reporting 0% beneficial ownership following an internal realignment.

Invesco Ltd. has reported a reduction in its beneficial ownership of Encompass Health Corp. common stock to 4.9%, falling below the 5% threshold.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a 4.0% beneficial ownership stake in Encompass Health Corporation as of December 31, 2024.